Cargando…

Challenges in Permeability Assessment for Oral Drug Product Development

Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key param...

Descripción completa

Detalles Bibliográficos
Autores principales: Koziolek, Mirko, Augustijns, Patrick, Berger, Constantin, Cristofoletti, Rodrigo, Dahlgren, David, Keemink, Janneke, Matsson, Pär, McCartney, Fiona, Metzger, Marco, Mezler, Mario, Niessen, Janis, Polli, James E., Vertzoni, Maria, Weitschies, Werner, Dressman, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609725/
https://www.ncbi.nlm.nih.gov/pubmed/37896157
http://dx.doi.org/10.3390/pharmaceutics15102397
_version_ 1785128080554065920
author Koziolek, Mirko
Augustijns, Patrick
Berger, Constantin
Cristofoletti, Rodrigo
Dahlgren, David
Keemink, Janneke
Matsson, Pär
McCartney, Fiona
Metzger, Marco
Mezler, Mario
Niessen, Janis
Polli, James E.
Vertzoni, Maria
Weitschies, Werner
Dressman, Jennifer
author_facet Koziolek, Mirko
Augustijns, Patrick
Berger, Constantin
Cristofoletti, Rodrigo
Dahlgren, David
Keemink, Janneke
Matsson, Pär
McCartney, Fiona
Metzger, Marco
Mezler, Mario
Niessen, Janis
Polli, James E.
Vertzoni, Maria
Weitschies, Werner
Dressman, Jennifer
author_sort Koziolek, Mirko
collection PubMed
description Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.
format Online
Article
Text
id pubmed-10609725
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106097252023-10-28 Challenges in Permeability Assessment for Oral Drug Product Development Koziolek, Mirko Augustijns, Patrick Berger, Constantin Cristofoletti, Rodrigo Dahlgren, David Keemink, Janneke Matsson, Pär McCartney, Fiona Metzger, Marco Mezler, Mario Niessen, Janis Polli, James E. Vertzoni, Maria Weitschies, Werner Dressman, Jennifer Pharmaceutics Review Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed. MDPI 2023-09-28 /pmc/articles/PMC10609725/ /pubmed/37896157 http://dx.doi.org/10.3390/pharmaceutics15102397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Koziolek, Mirko
Augustijns, Patrick
Berger, Constantin
Cristofoletti, Rodrigo
Dahlgren, David
Keemink, Janneke
Matsson, Pär
McCartney, Fiona
Metzger, Marco
Mezler, Mario
Niessen, Janis
Polli, James E.
Vertzoni, Maria
Weitschies, Werner
Dressman, Jennifer
Challenges in Permeability Assessment for Oral Drug Product Development
title Challenges in Permeability Assessment for Oral Drug Product Development
title_full Challenges in Permeability Assessment for Oral Drug Product Development
title_fullStr Challenges in Permeability Assessment for Oral Drug Product Development
title_full_unstemmed Challenges in Permeability Assessment for Oral Drug Product Development
title_short Challenges in Permeability Assessment for Oral Drug Product Development
title_sort challenges in permeability assessment for oral drug product development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609725/
https://www.ncbi.nlm.nih.gov/pubmed/37896157
http://dx.doi.org/10.3390/pharmaceutics15102397
work_keys_str_mv AT koziolekmirko challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT augustijnspatrick challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT bergerconstantin challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT cristofolettirodrigo challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT dahlgrendavid challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT keeminkjanneke challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT matssonpar challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT mccartneyfiona challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT metzgermarco challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT mezlermario challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT niessenjanis challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT pollijamese challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT vertzonimaria challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT weitschieswerner challengesinpermeabilityassessmentfororaldrugproductdevelopment
AT dressmanjennifer challengesinpermeabilityassessmentfororaldrugproductdevelopment